Skip to content

J Affect Disord

ISSN 0165-0327; 1573-2517;

8 papers in the library · 143 citations · publishing 2018-2026

Papers

Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.

J Affect Disord April 1, 2018 57 citations

An algorithm analyzing natural speech from baseline interviews can predict which patients with treatment-resistant depression will respond to psilocybin therapy. The approach uses vocal patterns and linguistic features to forecast treatment outcomes, suggesting that speech biomarkers may enable personalized medicine in mental health. This predictive capability could help identify likely responders before treatment begins, advancing precision psychiatry for depression.

DOI: 10.1016/j.jad.2018.01.006 Psychedelic therapy Psilocybin therapy Psilocybin treatment Depression treatment +17

Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity.

J Affect Disord February 27, 2024 31 citations

Brain scans taken before psilocybin therapy for depression can help predict who will benefit most. In a study of patients with treatment-resistant depression, patterns of functional connectivity in resting-state fMRI scans at baseline were associated with the degree of symptom improvement after psilocybin treatment. Specific neural signatures in the brain's default mode network and frontoparietal network showed predictive value for treatment response. These findings suggest that pre-treatment brain imaging may eventually help tailor psilocybin therapy to individuals most likely to respond.

DOI: 10.1016/j.jad.2024.02.089 Psychedelic therapy Psychedelic-assisted therapy Psilocybin therapy Psilocybin treatment +16

Virtual mindfulness interventions to promote well-being in adults: A mixed-methods systematic review.

J Affect Disord January 4, 2022 30 citations

A mixed-methods systematic review examined whether virtual mindfulness interventions improve well-being in adults. The review synthesized evidence from multiple studies and suggests that such interventions can reduce stress and enhance mental health, though the magnitude of effects varied across studies. The authors indicate that virtual formats offer accessible alternatives to in-person programs, but caution that the quality of evidence is limited by heterogeneity in study designs and outcome measures. No definitive conclusions about long-term benefits were drawn.

DOI: 10.1016/j.jad.2022.01.027 Full text Digital mindfulness. Mental health. Stress reduction. Research review.

Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms.

J Affect Disord December 27, 2022 24 citations

Certain subtypes of psychedelic experiences consistently and predictably reduce symptoms of depression and anxiety. The findings indicate that distinct patterns within a psychedelic journey can be linked to specific therapeutic outcomes, suggesting that the structure of the experience itself plays a role in mental health benefits.

DOI: 10.1016/j.jad.2022.12.042 Full text Psychedelic-assisted therapy Psychedelic experiences Psychedelic journeys Hallucinogenic experiences +20

Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3).

J Affect Disord May 16, 2026 1 citation

A panel of experts from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners used a Delphi process to develop consensus guidelines for administering intravenous ketamine infusions to treat depressive disorders. The guidelines provide recommendations on patient selection, dosing, safety monitoring, and treatment protocols, aiming to standardize clinical practice and improve patient outcomes. The consensus reflects agreement among specialists on best practices for this off-label use of ketamine.

DOI: 10.1016/j.jad.2026.121970

Changes in depression symptom network structure following ketamine treatment in treatment-resistant depression.

J Affect Disord May 14, 2026

Ketamine treatment alters the network structure of depression symptoms in people with treatment-resistant depression. The connections among symptoms, such as mood and sleep, shift after treatment, suggesting that ketamine may work by reorganizing how symptoms relate to one another rather than simply reducing overall severity.

DOI: 10.1016/j.jad.2026.121964

Multiple peripheral inflammatory markers in adolescents with major depressive disorder treated with repeated esketamine infusions: results from a randomized controlled trial.

J Affect Disord February 23, 2026

In a randomized controlled trial, adolescents with major depressive disorder who received repeated esketamine infusions showed changes in multiple peripheral inflammatory markers compared to those who received a placebo. The treatment was associated with reductions in certain inflammatory markers, suggesting that esketamine may influence immune system activity in this population. The findings indicate a potential link between the antidepressant effects of esketamine and its impact on inflammation, though the exact relationship requires further investigation.

DOI: 10.1016/j.jad.2026.121488